Use of MRI as an outcome measure in clinical trials in RA

被引：0
|
作者：
Annette H. M. van der Helm–van Mil
机构：
[1] Leiden University Medical Centre,Department of Rheumatology
来源：
Nature Reviews Rheumatology | 2012年 / 8卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Following a decade of substantial improvements in sensitivity and usability, MRI is increasingly used to assess primary outcomes of therapeutic trials in rheumatoid arthritis (RA). In the wake of an MRI-based evaluation of treatment efficacy, what lessons are emerging about the clinical value of this technique for patients with RA?
引用
收藏
页码：643 / 644
页数：1
相关论文
共 50 条
  • [31] LUNG CLEARANCE INDEX AS AN OUTCOME MEASURE IN CYSTIC FIBROSIS CLINICAL TRIALS
    Ratjen, F.
    Sheridan, H.
    Lee, P.
    Song, T.
    Stone, A.
    Davies, J. C.
    PEDIATRIC PULMONOLOGY, 2011, : 282 - 283
  • [32] Examining cutaneous disease activity as an outcome measure for clinical trials in dermatomyositis
    Gaffney, Rebecca G.
    Feng, Rui
    Pearson, David R.
    Tarazi, Meera
    Werth, Victoria P.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (06) : 1793 - 1794
  • [33] Muscle MRI as an outcome measure
    Diaz-Manera, J.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S121 - S121
  • [34] Examining cutaneous disease activity as an outcome measure for clinical trials in dermatomyositis
    Gaffney, R. G.
    Feng, R.
    Pearson, D.
    Tarazi, M.
    Werth, V. P.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S97 - S97
  • [35] Examining Cutaneous Disease Activity As an Outcome Measure for Clinical Trials in Dermatomyositis
    Gaffney, Rebecca
    Tarazi, Meera
    Feng, Rui
    Pearson, David
    Werth, Victoria P.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [36] Dystrophin as a biochemical outcome measure in Duchenne muscular dystrophy clinical trials
    Sardone, V.
    Ellis, M.
    Torelli, S.
    Feng, L.
    Chambers, D.
    Ricotti, V.
    Domingos, J. Pisco
    Phadke, R.
    Sewry, C. A.
    Morgan, J.
    Muntoni, F.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S16 - S16
  • [37] Patient retrospective evaluation of change: An appropriate outcome measure for clinical trials?
    Fischer, D
    Stewart, AL
    Bloch, DA
    Lorig, K
    Laurent, D
    Holman, HR
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S229 - S229
  • [38] A Psychometric Evaluation of the Motor-Behavioral Assessment Scale for Use as an Outcome Measure in Rett Syndrome Clinical Trials
    Raspa, Melissa
    Bann, Carla M.
    Gwaltney, Angela
    Benke, Timothy A.
    Fu, Cary
    Glaze, Daniel G.
    Haas, Richard
    Heydemann, Peter
    Jones, Mary
    Kaufmann, Walter E.
    Lieberman, David
    Marsh, Eric
    Peters, Sarika
    Ryther, Robin
    Standridge, Shannon
    Skinner, Steven A.
    Percy, Alan K.
    Neul, Jeffrey L.
    AJIDD-AMERICAN JOURNAL ON INTELLECTUAL AND DEVELOPMENTAL DISABILITIES, 2020, 125 (06): : 493 - 509
  • [39] The United Kingdom Neurological Disability Scale (UNDS): A novel outcome measure for use in Multiple Sclerosis clinical trials
    Sharrack, B
    Hughes, R
    Wiles, M
    Hawkins, S
    Young, C
    Soudain, S
    NEUROLOGY, 2004, 62 (07) : A226 - A227
  • [40] Interpretation of the Seattle Angina Questionnaire as an Outcome Measure in Clinical Trials and Clinical Care A Review
    Thomas, Merrill
    Jones, Philip G.
    Arnold, Suzanne V.
    Spertus, John A.
    JAMA CARDIOLOGY, 2021, 6 (05) : 593 - 599
12345